As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Nephros, Inc. The largest reported stake is Charles E. Davidson's, at 5.68%. 3 filings are on record since November 14, 2025 (Schedule 13G, September 16, 2026).
Sell to companies like Nephros, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Charles E. Davidson · Sole voting: 616,945 · Shared voting: 0 · Sole dispositive: 616,945 · Shared dispositive: 0 · SCHEDULE 13G, 2026-09-16
- · Reporting person: Wexford Capital LP · Sole voting: 0 · Shared voting: 223,539 · Sole dispositive: 0 · Shared dispositive: 223,539 · SCHEDULE 13D/A, 2026-09-16
- · Holder: Topline Capital Management, LLC · Percent: 5.6% · SCHEDULE 13G
Nephros, Inc. has 3 Schedule 13D or 13G filings on record since 2025-11-14. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 5.68% | 616,945 | SCHEDULE 13G, 2026-09-16 | 2026-09-14 | |
| Topline Capital Management, LLC | 5.6% | 595,334 | SCHEDULE 13G, 2025-11-14 | 2025-08-04 |
| Wexford Capital LP | 2.06% | 223,539 | SCHEDULE 13D/A, 2026-09-16 | 2026-09-14 |
Holding shares or following this stake? See who's behind Nephros, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Nephros, Inc. and the records around it.
Companies that share a holder
- Charles E. Davidson also filed stake reports on 1 other company: Mammoth Energy Services, Inc. (Jun 2026)
- Wexford Capital LP also filed stake reports on 5 other companies: MOBILICOM LIMITED (Jul 2026), Mammoth Energy Services, Inc. (Jun 2026), SOLITARIO RESOURCES CORP. (Feb 2026)
- Topline Capital Management, LLC also filed stake reports on 13 other companies: AMERICAN VANGUARD CORP (Feb 2026), GREEN DOT CORP (Feb 2026), KORU Medical Systems, Inc. (Feb 2026)
Watch Nephros, Inc.
Get an email when Nephros, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nephros, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nephros, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nephros, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Charles E. Davidson | 616,945 | 0 | 616,945 | 0 | SCHEDULE 13G, 2026-09-16 |
| CD Holding Company, LLC | 616,945 | 0 | 616,945 | 0 | SCHEDULE 13G, 2026-09-16 |
| Wexford Capital LP | 0 | 223,539 | 0 | 223,539 | SCHEDULE 13D/A, 2026-09-16 |
| Wexford GP LLC | 0 | 223,539 | 0 | 223,539 | SCHEDULE 13D/A, 2026-09-16 |
| Charles E. Davidson | 0 | 223,539 | 0 | 223,539 | SCHEDULE 13D/A, 2026-09-16 |
| Joseph M. Jacobs | 0 | 223,539 | 0 | 223,539 | SCHEDULE 13D/A, 2026-09-16 |
The latest filing identifies Nephros, Inc. by CUSIP 640671400 and gives its principal executive office as 380 Lackawanna Place, South Orange, NJ 7079 (SCHEDULE 13G, 2026-09-16).
What the percentages are based on
The information required by Item 4(b) is set forth in Row 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information in Row 11 is calculated on the basis of 10,860,120 shares of Common Stock issued and outstanding as of August 7, 2026, as reported by the Issuer in the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on August 10, 2026.Charles E. Davidson, SCHEDULE 13G, 2026-09-16
Source of funds (Item 3)
Not applicable.Wexford Capital LP, SCHEDULE 13D/A, 2026-09-16
Purpose of Transaction (Item 4)
Wexford Capital LP
Item 4 of the Statement is hereby amended to add the following: On September 14, 2026, Wexford Capital effected (i) an in-kind distribution of certain shares of common stock from Wexford Partners 11, L.P. ("WP11"), Wexford 11 Advisors LLC ("WP Advisors") and WPIC 2 LLC ("WPIC2", and together with WP11 and WP Advisors, the "Distributing Entities") to the underlying investors of the Distributing Entities that does not involve (a) a purchase or a sale of securities or (b) any additional consideration, and (ii) a sale of certain shares of common stock from the Distributing Entities to an entity controlled by Arthur Amron, a current director of the Issuer and a former employee of Wexford Capital, the proceeds of which were distributed to certain underlying investors of the Distributing Entities. No Distributing Entities shall receive any compensation, directly or indirectly, in connection with the transaction described herein.Item 4 of the SCHEDULE 13D/A filed 2026-09-16
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | Topline Capital Management, LLC | 5.6% | SCHEDULE 13G |
| 2026-09-16 | Charles E. Davidson | 5.68% | SCHEDULE 13G |
| 2026-09-16 | Wexford Capital LP | 2.06% | SCHEDULE 13D/A |
Questions about who owns Nephros, Inc.
Who owns Nephros, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Nephros, Inc.: Charles E. Davidson (5.68%, Schedule 13G, filed 2026-09-16) and Topline Capital Management, LLC (5.6%, Schedule 13G, filed 2025-11-14).
Who are the largest shareholders of Nephros, Inc.?
By the share each holder's latest filing reports, the largest holders of Nephros, Inc. on this page are Charles E. Davidson (5.68%) and Topline Capital Management, LLC (5.6%).
When did Charles E. Davidson buy into Nephros, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Charles E. Davidson on this page is the Schedule 13G, filed 2026-09-16, reporting 5.68%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Nephros, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.